Dendreon Corporation - A Dream Come True for Investors and Patients

April 14 - Tuesday was a shareholders dream come true for those invested in Dendreon Corporation (DNDN). After phase III clinical trials for the company's prostate cancer vaccine Provenge showed to increase the survival rate of patients, the company's share price soared over 175% within hours of trading.

"We've been saying for years the drug worked, we just did not know how many trials it would take to prove it to the FDA. This morning, we received our answer and it is a great one for guys everywhere with prostate cancer," said David Miller of Biotech Monthly.

The IMPACT study was designed to reduce the risk of death in prostate cancer patients by 22%. Details of the study will be presented at a medical conference on April 28. Previous studies of Provenge showed the drug to prolong survival by 4.5 months over placebo.

"Survival is the gold standard outcome for oncology clinical trials, and overall survival was the primary endpoint of the IMPACT trial. The positive results from this landmark study provide confirmatory evidence demonstrating that treatment with PROVENGE may prolong survival," said Dendreon CEO Mitch Gold, in a statement.

On a conference call Tuesday morning, Gold said that the Provenge results from the IMPACT study were "unambiguous" and "consistent" with previous studies of the cancer vaccine.

Dendreon's next move will be to submit the results to the U.S. Food and Drug Administration in the middle of 2009 and an approval decision could be made as early as the second quarter of 2010.

To all who benefit from this: Congratulations!